Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07218211 · ClinicalTrials.gov registry record · Phase 4

Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP

A Phase 4 study of HIV Prevention and HIV Pre-exposure Prophylaxis, sponsored by Duke University.

Recruiting
Registry status
Phase 4
Development phase
100
Enrollment target
1
Study location

NCT07218211: Recruiting Phase 4 study of HIV Prevention and HIV Pre-exposure Prophylaxis, sponsored by Duke University.

NCT07218211 is a Phase 4 study of HIV Prevention and HIV Pre-exposure Prophylaxis that is actively recruiting participants, run by Duke University. The registered enrollment target is 100 participants, below the 379-participant average among 32 other HIV Prevention trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07218211, a Phase 4 study of HIV Prevention and HIV Pre-exposure Prophylaxis, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
Phase 4
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The purpose of this project is to test a culturally-tailored, community-delivered long-acting injectable PrEP (lenacapavir) program for Latine gay and bisexual men (GBM) and transgender women (TGW). The objective is to evaluate whether this intervention demonstrates greater persistence on lenacapavir for Latine GBM and TGW compared with what has been observed historically at the Duke PrEP Clinic.

Primary Outcome

Measured using an adapted Abbreviated Acceptability Rating Profile. Items are rated on a 5-point Likert scale from 1 (Strongly disagree) to 5 (Strongly agree); higher scores indicate greater acceptability of the intervention.

Interventions

  • DRUG Lenacapavir long-acting

Study Locations (1)

North Carolina

  • El Centro Hispano - Durham

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2026-01-13
Est. Completion 2028-01-05
Phase Phase 4
Duke University

1,725 total trials

What NCT07218211 shows while recruiting

NCT07218211 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 379-participant average among 32 other HIV Prevention trials with a reported enrollment target (74% lower).

The record links to 5 conditions, with HIV Prevention appearing as the primary indexed condition, and to 1 intervention - of which Lenacapavir long-acting is the first listed.

NCT07218211 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT07218211 about?

NCT07218211 is a clinical study titled "Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP". The purpose of this project is to test a culturally-tailored, community-delivered long-acting injectable PrEP (lenacapavir) program for Latine gay and bisexual men (GBM) and transgender women (TGW). The objective is to evaluate whether this intervention demonstrates greater persistence on lenacapavi...

What is the current status of trial NCT07218211?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2026-01-13. Estimated completion is 2028-01-05.

What conditions does trial NCT07218211 study?

This clinical trial studies the following conditions: HIV Prevention, HIV Pre-exposure Prophylaxis, HIV Prevention Program, HIV Prevention and Care, HIV Pre-exposure Prophylaxis Use.

What interventions are being tested in trial NCT07218211?

The interventions under investigation include: Lenacapavir long-acting (DRUG).

Who is sponsoring clinical trial NCT07218211?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07218211 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Prevention

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07218211's enrollment target sits among peer trials

100 18th of 32 higher than 13 of 32 other HIV Prevention trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Prevention trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07218211, the US trial registry maintained by the National Library of Medicine. NCT07218211 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.